Moreover, FUBP1 overexpression dramatically reduced osteosarcoma sensitivity to lobaplatin both in vitro and in vivo, whereas silencing FUBP1 enhanced osteosarcoma sensitivity. Here, FUBP1 is linked to osteosarcoma.